Member Press Releases

Breakthrough SAMBA II point-of-care diagnostic machine on show to the public from this November, as part of inspiring COVID-19 science showcase.

RQM+, the leading MedTech service provider with the world’s largest global team of regulatory and quality experts, today announced the launch of its reimbursement division. RQM+ now provides comprehensive reimbursement services in addition to regulatory, quality, clinical and laboratory services – supporting market access throughout the entire product lifecycle for medical devices and diagnostics.

RQM+, the leading MedTech service provider with the world’s largest global team of regulatory and quality experts, and portfolio company of Linden Capital Partners, today announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive regulatory, quality, clinical and laboratory services, supporting market access throughout the entire product lifecycle for medical devices and diagnostics.

A collaboration between the North East Innovation Lab and the National Institute for Health and Care Research (NIHR) Newcastle In Vitro Diagnostics Co-operative has secured joint funding of around £20,000.

New Board members will provide expert insight into ADME-Tox, biomarker, assay, cell and gene therapy, and immuno-oncology advances.

The North East Innovation Lab has played a key role in a successful study to develop a new biosensor which could be used in Covid-19 diagnostic tests.

New combined tests deliver highly accurate point-of-care detection for SARS-CoV-2, Flu A, Flu B and RSV – boosting infection control in hospitals and speeding patient access to urgent care.

New multiplex panel can detect SARS CoV 2, Flu A Flu B RSV at the Point of Need and can deliver accurate PCR results in approximately 30 minutes.

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has chosen it to supply biosamples for the Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD) Project.

LSG has recently completed a move to new, larger facilities in Sandy, Bedfordshire. The facilities will offer expanded manufacturing capabilities available in new cleanroom suites equipped to GMP standards.